Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial

Inclusion Criteria: * Age ≥18 years * Evidence of primary or recurrent HGG that in the opinion of the treating team would require surgical resection * Karnofsky Performance Score (KPS) ≥ 60% * ECOG ≤ 2 * Life expectancy greater than 12 weeks * Adequate liver function defined as ALT, AST, ALP within 1.5x institutional upper limit of normal (for study drug arm only) * Ability to swallow medication (for study drug arm only) * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation (for study drug arm only) * Ability to understand and willingness to sign a written informed consent document * Be able to comply with treatment plan, study procedures and follow-up examinations Exclusion Criteria: * Patients may not be receiving any other investigational agents while on study * Patients who have known allergy to posaconazole or other azoles (for study drug arm only) * Patients who have previously had a severe side effect, such as agranulocytosis and neutropenia, in conjunction with previous azole class drugs for a parasitic infection (for study drug arm only) * Patients with a history of acute or chronic hepatitis (for study drug arm only) * Patients with liver enzymes (ALT, AST, ALP) \>1.5x above normal range for the laboratory performing the test (for study drug arm only) * Patients who are taking metronidazole and cannot be safely moved to a different antib…